Jing-Yue Wang1†
Quan-Wei Wang1†
Xin-Yu Yang1
Wei Yang1Dong-Rui Li1
Jing-Yu Jin1Hui-Cong Zhang1
Xian-Feng Zhang2*- 1Department of Cardiovascular Medicine, The First Hospital of Jilin University, Changchun, China
- 2Department of Neurosurgery, The First Hospital of Jilin University, Changchun, China
Obesity is a complex disease characterized by excessive fat accumulation which is caused by genetic, environmental and other factors. In recent years, there has been an increase in the morbidity, disability rate,and mortality due to obesity, making it great threat to people’s health and lives, and increasing public health care expenses. Evidence from previous studies show that weight loss can significantly reduce the risk of obesity-related complications and chronic diseases. Diet control, moderate exercise, behavior modification programs, bariatric surgery and prescription drug treatment are the major interventions used to help people lose weight. Among them, anti-obesity drugs have high compliance rates and cause noticeable short-term effects in reducing obese levels. However, given the safety or effectiveness concerns of anti-obesity drugs, many of the currently used drugs have limited clinical use. Glucagon-like peptide-1 receptor (GLP-1R) agonists are a group of drugs that targets incretin hormone action, and its receptors are widely distributed in nerves, islets, heart, lung, skin, and other organs. Several animal experiments and clinical trials have demonstrated that GLP-1R agonists are more effective in treating or preventing obesity. Therefore, GLP-1R agonists are promising agents for the treatment of obese individuals. This review describes evidence from previous research on the effects of GLP-1R agonists on obesity. We anticipate that this review will generate data that will help biomedical researchers or clinical workers develop obesity treatments based on GLP-1R agonists.
1 Introduction
In the past decade, obesity and related co-morbidities have become critical public health problems and serious medical conditions worldwide (1). A state of positive energy balance exists in the duration of the energy intake exceeding energy consumption, resulting in the storage of the excess calories in adipose tissue, which first leads to body phenotypic overweight (body mass index, BMI 25-30 kg/m2). It then develops into a weight disorder called obesity, defined as a BMI ≥30 kg/m2 (2). In pathology classification, there is no clear consensus on terminology. The most important sub-groups reviewed include abnormal metabolic obesity, normal metabolic obesity, abnormal metabolic weight, normal metabolic weight, and sarcopenic obesity (3). In Europe, the incidence of obesity is five times higher than it was after World War II, and the number of obese people doubles yearly (4). A study of BRICS (Brazil, Russia, India, China, and South Africa) countries during 2007-2010 found that obesity was associated with hypertension, angina, diabetes, and arthritis (5). Obesity is not just a risk factor for other diseases, such as cardiovascular diseases, type 2 diabetes (T2DM), arthritis, and some cancers (6), but also a complex disease with multiple causes, which has its own disabling ability, pathophysiology, and co-morbidities (7). Obesity dramatically increases the risk of diseases and disables ability. Herein, it is a significant health challenge that leads to a decline in life quality and life expectancy. So far, in the long run, obesity prevention and treatment strategies-whether at the individual or group level, have not been very successful (8). Lifestyle and behavioral interventions aimed at reducing calorie intake and increasing energy expenditure have limited effects because complex and lasting hormonal, metabolic and neurochemical adaptations can prevent weight loss and promote weight recovery (8). A systematic review and meta-analysis proved that weight loss had been shown to prevent and mitigate obesity-related complications (9). Weight-loss surgery effectively reduces weight and complications in patients with severe obesity; however, weight gain is a common complication following surgery (10). An intragastric balloon (IGB) is a usually safe, reversible, and less invasive way to cause weight loss based on occupying stomach space to increase satiety. However, regarding weight loss, the results of using IGBs cannot be compared with bariatric surgery (11). Drug therapy for weight loss has made significant progress. However, many anti-obesity agents that have entered human clinical trials have shown unacceptable adverse events; many of them cannot be used for more than 3 months; the curative effect is moderate and suboptimal in the long term (12). The leptin-melanocortin axis, the opioid system, glucagon-like peptide-1 (GLP-1)/glucagon-like peptide-1 receptor (GLP-1R) system, and fibroblast growth factor 21 (FGF21)/its receptor complex FGFR1c/β-klotho axis are several common pathways confirmed by researches and pharmacological targets that play an essential role in regulating energy balance and feeding behavior (2). GLP-1 analogs and GLP-1R agonists can exert hypoglycemic effects and reduce weight. However, natural GLP-1 can easily be degraded by dipeptidyl peptidase 4 (DPP-4) in vivo and lose its activity. In order to make GLP-1 better used in the clinic, drug developers modified its structure and developed a series of GLP-1R agonists (13). Many clinical trials have proven GLP-1R agonists’ effectiveness and safety in treating or preventing obesity (14).
GLP-1, a 30- or 31-amino-acid-long peptide hormone, is a gastrointestinal peptide secreted by the intestinal tract that potentiates insulin release and reduces glucagon’s concentration in physiological conditions (15, 16). In 1983, it was found to be a cleavage product of proglucagon processing and secreted by intestinal epithelial endocrine L cells (17). It also comes from α-cells in the pancreatic islet and neurons in the nucleus of the solitary tract (18). GLP-1 is necessary for standard glucose tolerance and functions through specific GLP-1Rs, which belong to the G-protein-coupled glucagon receptor family, expressed in islet β-cells and stomach, small intestine, mucosa, heart, and other cell types (18, 19). GLP-1R agonists are a group of drugs based on the entero-insular axis (19). D’Alessio et al. (18) demonstrated that circulating peptides mediate insulinotropic activity with either bariatric surgery or treatment with long-acting GLP-1R agonists. Therefore, GLP-1R agonists may be new and promising treatment alternatives for obese subjects. However, the mechanism of GLP-1R in treating obesity is still uncertain, and more clinical evidence is needed for its long-term safety and efficacy. A schematic overview of GLP-1R agonists is summarized in Scheme 1. The possible mechanisms of weight loss caused by GLP-1R agonists is shown in Figure 1. Comparisons of common weight loss drugs are made in Table 1.
Scheme 1 A schematic overview of GLP-1 receptor agonists: classification, drug safety, and effectiveness. GI, Gastrointestinal; GLP-1R, Glucagon-like peptide-1 receptor; PEG, Polyethylene glycol. *Liraglutide and Semaglutide have been approved by the United States Food and Drug Administration for weight loss.
Figure 1 The possible mechanisms of weight loss caused by GLP-1. GI, Gastrointestinal; GLP-1, Glucagon-like peptide-1; GLP-1R, Glucagon-like peptide-1 receptor. Created with BioRender.com.
Table 1 Anti-obesity drugs: principal categories, functions, side effects, half-life and usage (20, 21).
2 Relationship between GLP-1 and obesity
The mechanism for the decrease in GLP-1 secretion is incompletely understood in obese people. Ranganath (22) et al. believe that the decrease of GLP-1 in obese subjects may be related to increased plasma non-esterified fatty acids (NEFA). Two clinical studies in simple obesity patients found that higher fasting and postprandial NEFA levels, the insulin-promoting effect of GLP-1 and its postulated role as a satiety factor may inhibit nutrition-mediated secretion (23).
In the central nervous system, proglucagon and proglucagon-derived peptides (GLP-1, glucagon-like peptide-2, GLP-2, and oxyntomodulin, OXM) are only present in a small group of neurons in the nucleus tractus solitarius (24, 25). These constitute the neural pathway that connects the “visceral sensory” brainstem and the hypothalamic nucleus to participate in energy homeostasis. Experiments on mice have shown that intraventricular administration of GLP-1, GLP-2, and OXM could significantly reduce food intake (25, 26). Central GLP-1 activation may be combined with GLP-2 and/or OXM activation to form a potential pharmacological tool to reduce meal intake and possibly increase energy consumption (25, 27). The expression of GLP-1 and/or GLP-1R was found in hypothalamic feeding centers (28, 29), hindbrain matrix (30), the lateral parabrachial nucleus of the posterior nucleus (31), and mesolimbic substrates (32–34), etc. parts which directly effect on appetite and lead to weight loss.
In addition, the GLP-1 can inhibit postprandial gastric emptying and reduce gastric acid secretion, inhibit gastric and duodenal peristalsis by inhibiting vagus nerve, and increase the pressure of pylorus, thus reducing appetite, causing a reduction in body weight and participating in the so-called “ileal braking” effect (19, 35). Beiroa (36) et al. injected GLP-1 analog, liraglutide (LIR), into mice. LIR was found to stimulate the thermogenesis of brown adipose tissue and the browning of adipose cells, independent of the intake of nutrients. It can increase the thermogenesis and utilization of triacylglycerol-derived fatty acids and glucose in brown adipocytes and reduce the lipid content through the central GLP-1R agonists’ signaling pathway, such as central AMP-activated protein kinase or sirtuin-1 (SIRT1), also known as NAD-dependent deacetylase SIRT1 (36–39).
3 Experimental evidence of GLP-1R agonists
GLP-1R agonists can be divided into short-acting and long-acting preparations according to the time-effect and the volume of injections. Short-acting preparations include beinaglutide (BN) and exenatide (EX), which generally need to be injected 2-3 times a day. Long-acting preparations include lixisenatide (LIXI) and LIR, which are injected once a day. Long-acting preparations also include semaglutide (SMG), dulaglutide (DUL), long-acting release formulation of exenatide (EX-LAR), and polyethylene glycol loxenatide (PEX-168), which generally need to be injected once a week. The data in this section is from animal and human trials.
3.1 Short−acting GLP−1 receptor agonists
3.1.1 Beinaglutide
BN is a recombinant human GLP-1(7-36) acid, obtained by genetic engineering technology, and the amino acid sequence of its active component is the same as that of GLP-1 in the human body. As the first original research drug in the field of diabetes in China, it has been recommended for meal injection and approved for the hypoglycemic intervention of T2DM (40), especially for patients with poor blood glucose control by metformin alone. BN can also be used for patients with poor blood glucose control alone. The starting dose is 0.1 mg (50 µl) three times daily and is injected subcutaneously 5 minutes before meals. After 2 weeks of treatment, the dose should be increased to 0.2 mg (100 µl) three times daily. This product has a half-life of about 11 minutes and can effectively control blood glucose within 2 hours after the meal. The drug is quickly eliminated in the body without accumulation.
In clinical studies, Wang (41) et al. included 36 patients (T2DM) with BMI ≥ 24 kg/m2. After treatment with BN for 3 months, BMI, fasting blood glucose, glycosylated hemoglobin, visceral and subcutaneous fat, silk protein E1, leptin, C-reactive protein (CRP), and tumor necrosis factor decreased significantly; the level of CRP is related to the weight loss percentage treated with BN. A real-world study from China evaluated the actual efficacy of BN in treating overweight/obese T2DM patients in an actual diagnosis and treatment environment. The study found that the average weight decreased by 10.05 kg after 3 months of treatment (40). In animal studies, Fang (42) et al. studied the pharmacological and pharmacokinetic efficacy of BN in C57BL/6 and ob/ob mice. Results showed that BN could reduce glucose levels, improve insulin secretion in glucose tolerance tests in a dose-dependent manner, and inhibit food intake and gastric emptying. BN inhibited meal intake at higher doses for more than 4 hours, leading to weight loss in ob/ob mice after about two weeks of treatment. In the nonalcoholic steatohepatitis (NASH) model, BN can reduce liver weight and steatosis and improve insulin sensitivity. There were significant changes in fatty acid β-oxidation (Ppara, Acadl, Acox1), mitochondrial function (Mfn1, Mfn2), antioxidation (Sod2), SIRT1. This suggests that BN may be an effective treatment for obesity and NASH (42). A clinical study involving 78 non-diabetic overweight/obese patients found that BN may be a more effective treatment option for overweight/obese Chinese than metformin (43). For example, a patient with a BMI of 17.96 kg/m2 found that BN did not make him lose weight but increased it. The researcher believes that it may be related to the patient’s habit of excessive intake (44). An animal experiment on mice found that the mechanism of BN treating obesity is targeting the composition of major lipid classes and the expression of genes in lipid metabolism in adipose tissue to counteract high-fat diet-induced obesity (45).
BN can reduce body weight, inhibit inflammatory reactions, directly be excreted by the kidney, and have fewer adverse reactions. However, relevant research on it has not been found abroad. In the future, more prospective randomized controlled clinical studies can be conducted for patients with diabetic obesity or simple obesity.
3.1.2 Exenatide
As the first GLP-1R agonist approved for T2DM, EX is a new class of compound and a synthetic product of exendin-4, which is a compound naturally derived from the Gila monster and has multiple hypoglycemic mechanisms: inhibiting of glucagon release from α cells, slowing of gastric emptying, decreasing appetite and increasing glucose-dependent insulin secretion (12, 46, 47). It is similar to human GLP-1 in function (46). Human GLP-1 was rapidly degraded by DPP-4, while EX showed prolonged kinetics because of its resistance to proteolysis of DPP-4 (48). EX has a relatively short half-life of 2.4 hours, which can be detected in plasma within 15 minutes after administration, and can still be detected 15 hours after a single subcutaneous injection > 0.2 µg/kg (12).
Lipotoxicity induced by saturated free fatty acids plays a vital role in renal injury in obese patients (49). It is found that EX can reverse the damage of renal tubular epithelial cells caused by a high-fat diet, and its effect is applied to simvastatin by reversing the down-regulation of SIRT1, preventing the production of reactive oxygen species and inhibiting the apoptosis of mitochondria (50).
There is little research on the weight loss effect of EX on simple obesity patients, and more clinical trials are conducted on patients with T2DM. A randomized, double-blind, placebo-controlled, parallel-group study showed that among the patients with T2DM treated with EX monotherapy, EX could improve glycated hemoglobin, fasting blood glucose, and postprandial blood glucose control, reduce weight, improve β cell function, and adjust blood pressure. EX is well tolerated (51). In a triple-blind, placebo-controlled 30-week clinical study involving patients with T2DM with a BMI of 33 ± 6 kg/m2, it was found that the weight loss in the EX treatment group was significantly higher than that in the control group. The primary adverse reaction to EX is nausea, suggesting that nausea may be the primary mechanism of weight loss (52). A 24-week multicenter, randomized, double-blind, placebo-controlled clinical study conducted by Apovian (53) found that EX combined with lifestyle adjustment could significantly reduce the weight of patients, all of which were 6.16 ± 0.54 kg. However, the incidence of nausea was higher than that of the control group. At present, the studies of EX on non-diabetic obesity mainly include 152 cases of simple obesity (weight loss of 5.1 kg) (54), 60 cases of polycystic ovary syndrome (weight loss of 3.2-6.0 kg) (55), and 10 cases of metabolic syndrome (weight loss of 3.7 kg) (56), among which the most common adverse reaction is still vomiting.
To sum up, EX can reduce the weight of diabetic patients with or without obesity, and it can also reduce the weight of simple obesity and polycystic ovary syndrome/metabolic syndrome with obesity. Clinical trials have shown that it has the potential to cause weight loss in non-diabetic obese individuals (57). The disadvantage is that it can cause vomiting; injection therapy is not convenient. Thus, more prospective clinical studies on non-diabetic obese patients are needed.
3.2 Long−acting GLP−1 receptor agonists: once-daily
3.2.1 Lixisenatide
LIXI is a once-daily GLP-1R agonist. As a synthetic analog of its endogenous exendin-4, compared with exendin-4, LIXI deleted one proline and added six lysine residues, which increased its binding affinity with the GLP-1R by four times and increased its circulating half-life (58, 59). Furthermore, the dissociation rate with the receptor is slow, and the high affinity and slow dissociation with the receptor prolongs the time of pharmacological effect (58, 60). The indication is to effectively reduce glycosylated hemoglobin levels in patients with T2DM by reducing fasting and postprandial blood glucose levels (61, 62). LIXI is administered subcutaneously, quickly absorbed into the blood, without biotransformation in the liver, and is degraded by proteolytic enzyme and then eliminated by the kidney (63, 64). Along with its role in lowering blood glucose levels, LIXI has many other functions, such as cardiovascular benefits, delaying gastric emptying, protective effect on pancreatic beta-cells, and increased insulin mRNA expression and hormone secretion (65). Also, LIXI is well tolerated, and nausea and vomiting are the most commonly reported adverse events (66, 67).
A prospective clinical study from Spain found that besides controlling blood glucose (fasting blood glucose and glycosylated hemoglobin), LIXI can also improve blood lipids, especially total cholesterol and triglyceride (68). The exact mechanism may be that LIXI reduces chylomicron triacylglycerol by delaying gastric emptying by increased clearance (69). In iGlarLixi (insulin glargine: LIXI = 1:1) study, adult Japanese patients with T2DM lost more weight compared to the iGlar (insulin glargine U100) study (-0.51 kg vs. +0.55 kg). However, iGlarLixi patients had more gastrointestinal-related adverse, primarily nausea (16.9% vs. 0.8%) in this 26-week, randomized, open-label study (70). At the same time, the research of GetGoal-Duo1 and GetGoal-L also found that when the basic insulin treatment was not effective, the combination of LIXI could not only significantly improve fasting blood glucose and glycosylated hemoglobin but also significantly reduce weight, with the weight dropping by 0.9 kg and 1.3 kg respectively (71). In GetGoal-S, a subanalysis of GetGoal-S and GetGoal-F1 studies, they found that LIXI could significantly reduce subjects’ body weight (− 1.76 ± 0.20 kg;-1.12 kg; -2.6/2.7 kg), respectively (72–74). The main adverse events of LIXI are gastrointestinal adverse reactions, mainly manifested as nausea and vomiting in the initial stage (75, 76). Compared with EX, the frequency of subcutaneous injection of LIXI is less, and the incidence of gastrointestinal adverse reactions and hypoglycemia is lower. Compared with LIXI, LIR is more effective in improving blood glucose and reducing weight, and both treatments are well tolerated (75, 77, 78).
In clinical studies, LIXI has shown the benefits of weight loss, which is well tolerated by patients and can meet the needs of overweight patients for weight control. Given that there are no major, obvious differences in tolerability, efficacy on glycemic parameters, weight loss, or overt advantages regarding administration, it is likely that the use of LIXI in place of other GLP-1 agonists will be based on cost (79).
3.2.2 Liraglutide
LIR was formed by adding a 16-carbon palmitoyl fatty acid to the 26th position of GLP-1 by gene recombination technology and replacing the 34th position of lysine on GLP-1 with arginine. These structural modifications increase aggregation and promote non-covalent binding of the albumin, thus inhibiting the DPP-4, which is injected subcutaneously in the form of isotonic fluid. LIR is suitable to be administered once a day, with a tmax of 9~13 hours and t1/2 of 13 hours (80–82). Clinically, it is mainly used to treat T2DM and causes weight reduction when used in large doses (3mg/day) (83). The United States Food and Drug Administration (FDA) approved it to treat obesity. Its main principles include that it can inhibit the feeding center, thus reducing appetite; it can delay gastric emptying, resulting in slow digestion and absorption of food, to achieve the role of diet control (84–86).
Compared with the treatment of short-acting GLP-1R agonists, LIR has a greater improvement in lowering glycated hemoglobin and fasting blood glucose. It has fewer side effects than EX twice a day (87). A clinical study involving 564 adults (BMI 30-40 kg/m2, without T2DM) found that compared with orlistat (3×120 mg, weight loss of 4.1 kg), LIR (subcutaneous administration of 1.2 mg/d, 1.8 mg/d, 2.4 mg/d or 3 mg/d) had an average weight loss of 4.8-7.2 kg, the two-year extended experiment of which also showed similar results (88, 89). The relevant study also found that the 1-year average weight loss of participants (LIR 3.0 mg) was 9.2 kg reporting nausea/vomiting episodes, while that of participants without nausea/vomiting was 6.3 kg. Researchers believe that nausea/vomiting is related to greater weight loss (90). A three-year obesity and prediabetes trial found that LIR 3 mg can improve health benefits in reducing the diabetes risk of patients with obesity and prediabetes (91). Pi-Sunyer (92) et al. enrolled 3731 patients without T2DM (BMI ≥ 27 kg/m2 or 30 kg/m2) and gave LIR 3mg daily subcutaneous injection. After 56 weeks of treatment, the average weight loss of the patients was 8.40 ± 7.3 kg, and the most common adverse reactions were mild or moderate nausea and diarrhea. A 56-week trial included 422 patients with BMI≥30 kg/m2 or BMI≥27 kg/m2 with dyslipidemia and/or hypertension (non-diabetic). These patients reduced their initial weight by ≥5% through a low-calorie diet during the 4-12 weeks pre-trial induction period. It was found that more patients in the LIR group than the placebo group maintained their weight loss by ≥5%, which indicated that LIR 3.0 mg/d is expected to improve the maintenance of weight loss (93).
GLP-1 analog has 97% homology with human GLP-1 and has been approved for the clinical treatment of diabetes and obesity. However, it should be noted that combined with insulin may lead to hypoglycemia (94). It is worth mentioning that China's FDA said that the application for a marketing license for LIR injection for obesity or overweight indications had been accepted, which was the first time that the weight control indications of GLP-1R agonists have been accepted in China.
3.3 Long-acting GLP−1 receptor agonists: Once-weekly
3.3.1 Semaglutide
SMG is an analog of long-acting GLP-1, mainly used to control T2DM, and is also suitable for promoting weight loss in people with mild obesity (95, 96). The usage for treating obesity is subcutaneous injection once a week. For both diabetic and non-diabetic patients, the drug can reduce weight (97, 98). Here, we mainly summarize the relevant experiments on the SMG treatment effect in people with obesity (STEP) programs.
More than 1,200 patients with T2DM complicated with obesity were randomly divided into 1mg SMG group, 2.4mg SMG group, or placebo group and given once a week in STEP2 research. The weight loss ranges of the two treatment groups were -6.9 kg (-7%) and -9.7 kg (-9.6%), respectively. The 2.4 mg group lost the most weight, which means that among adults suffering from overweight or obesity and T2DM, SMG 2.4 mg once a week has achieved significant clinically significant weight loss (99). In the STEP1 trial (100), Wilding et al. recruited 1961 non-diabetic adults with a BMI of 30 kg/m2 (or ≥27 kg/m2 with more than 1 body weight-related coexisting disease). The SMG group (once 2.4 mg, once a week) was treated for 68 weeks, and the average weight loss in the SMG group was 15.3 kg. More patients in the SMG group achieved a weight loss of ≥ 5% (86.4% vs. 31.5%), ≥ 10% (69.1% vs. 12.0%), and ≥ 15% (50.5% vs. 4.9%), compared with the placebo group. STEP 8 and STEP 3 showed similar results (101, 102).
In the United States, oral and injectable forms of SMG are approved for treating T2DM, while only injectable forms are approved for treating obesity (103). Like other GLP-1R agonists, SMG often causes adverse reactions. The main adverse reactions were gastrointestinal side effects, including nausea, diarrhea, and vomiting. These adverse reactions are generally mild to moderate and gradually alleviated in most patients (100, 104). Like LIR, the race of patients involved in related clinical studies is relatively small. More clinical trials aimed at obese people in Asia and Africa are expected to prove its effectiveness and safety. Regarding the treatment of obesity, we expect SMG to be approved by more countries’ FDA in the future.
3.3.2 Dulaglutide
DUL is a long-acting GLP-1R agonist which can promote insulin secretion, inhibit gastric emptying, and reduce appetite. It is approved for treating hyperglycemia in patients with T2DM in many countries (105, 106). Like other GLP-1R agonists, when used alone or treated with non-insulin secretagogues, DUL treatment is associated with weight loss or decreased weight gain (107). It has a long half-life period and is injected once a week. The average peak time of subcutaneous injection is 48 hours. The most common adverse reactions were nausea, headache, vomiting, and diarrhea (108). Among them, gastrointestinal adverse reactions mainly occurred in the early stage of the first drug use, with mild to moderate degrees (109). Here, we mainly summarize the relevant research on assessing the weekly administration of DUL (AWARD).
AWARD-6 is a randomized, open, parallel-grouped, multicenter, phase 3, non-inferiority study comparing the safety and efficacy of weekly DUL and daily LIR in patients with uncontrolled T2DM treated with metformin. Compared with LIR once a day, once weekly subcutaneous injection of DUL similarly lowers body weight: –2.90 kg (-3.61 kg for LIR) after 26 weeks of treatment (109). At 26 weeks after treatment, the weight loss was -2.29 ± 0.24 kg for 1.5 mg DUL, -1.36 ± 0.24 kg for 0.75 mg DUL, and -2.22 ± 0.24 kg for metformin (110). In patients with T2DM who are poorly controlled by metformin, increasing DUL from 1.5mg to 3.0mg or 4.5mg can provide glycosylated hemoglobin and weight loss related to clinically relevant doses and has similar safety (111). It is worth mentioning that in the AWARD-2 study, there were several cases of pancreatitis caused by DUL (112). Therefore, during DUL treatment, we should pay close attention to the related signs of pancreatitis, and if pancreatitis occurs, we need to stop the drug immediately (113).
In summary, the recommended clinical treatment for diabetes is 0.75 mg or 1.5 mg. Studies have found that higher doses can further reduce glycosylated hemoglobin and body weight, and the safety is similar to low doses. However, DUL’s long-term efficacy and safety need to be further studied.
3.3.3 Long-acting release formulation of exenatide (Microspheres)
Polymer materials commonly used in microsphere preparation are polylactic-co-glycolic acid (PLGA), which is approved by FDA and has good safety and biodegradability. It is often used as a drug carrier and biological scaffold. EX microspheres are a long-acting release of EX. After weekly subcutaneous injection, EX was slowly released from the microspheres by diffusion and microsphere rupture and reached a stable plasma concentration about 6-8 weeks after treatment (114). Nausea and vomiting are less frequent in patients receiving EX-LAR than in patients taking EX (114).
A 30-week randomized non-inferiority study comparing 2 mg once-weekly EX-LAR with 10 µg twice-daily EX in 295 patients with T2DM. In terms of weight loss, there was no significant difference between weight loss with EX (-3.6 kg) and with EX-LAR (-3.7 kg) (115). A study involving treatment up to 104 or 117 weeks in 134 patients with T2DM showed EX microspheres-naïve patients experienced weight reductions of -2.7 kg (116). Hirsch et al. (117) found that after 24 weeks of drug treatment of once-weekly EX-LAR or dapagliflozin or co-administered, nondiabetic women with a BMI (≥30 kg/m2 and ≤ 45 kg/m2) and polycystic ovary syndrome all lost weight. Among them, weight loss was the most in the double treatment.
Once-weekly treatment with EX-LAR (considering the potential beneficial effects of GLP-1R activation on β cells and weight loss associated with many patients) is a promising potential strategy for diabetes prevention. Similarly, once-weekly EX-LAR preparation can be used as an anti-obesity treatment in patients without T2DM or impaired glucose tolerance (118). EX long-acting preparation can reduce weight, but there are few related clinical studies, and most focus on patients with T2DM.
3.3.4 Polyethylene glycol loxenatide
The early GLP-1R agonist has many defects, such as multiple injections and a high incidence of adverse reactions in the digestive tract, which limits its clinical application. PEX-168 is a new agent of long-acting GLP-1R agonist, which is molecularly modified from EX via amino acid modification and PEGylation (119), the first GLP-1R agonist modified by PEG to achieve long-term pharmacological action (120, 121). It has the advantages of a prolonged administration interval (once a week), few adverse reactions in the digestive tract (122), and adverse effects reported ranging from ‘mild’ to ‘moderate’ (122, 123).
Guo (120) et al. found that PEX-168 significantly reduced the body weight of simple obese mice. The weight loss of the low dose (0.03 mg/kg) group, medium dose (0.1 mg/kg) group, and high dose (0.33 mg/kg) group were about 2g, 4g, and 1g (8 weeks). A multicenter, randomized, double-blind, multiple dose-escalation study showed that after 4 weeks of treatment of PEX-168 with different doses, the weight decreased by -0.8-1.8kg. After 8 weeks of treatment, the weight decreased by -1.4-3.3kg (122).
PEX-168 is a China-domestic long-acting GLP-1R agonist approved by the China's FDA for marketing and used for blood glucose control of adult patients with T2DM.
4 Others: GIPR/GLP-1R dual agonists and GIPR/GLP-1R/GCGR triagonists
Intestinal endocrine K cells produce gastric inhibitory polypeptide (GIP). Like GLP-1, GIP stimulates insulin secretion from pancreatic β cells in a glucose-dependent manner (124). Glucagon (GCG) is a 29 amino acid peptide secreted by pancreatic α cells when blood glucose levels are low. Its ability to increase energy expenditure has been known for over 60 years (125). Recently, several multi-targeting agonists of GIPR, GLP-1R, or GCGR for treating T2DM and obesity have been in clinical trials. These agonists are developed to maximize metabolic benefits and reduce side effects (126). Therefore, the research and development of the relevant drugs and the replacement therapy of double GIP-GLP-1R agonists (e.g., tirzepatide) and triple GIP-GCG-GLP-1R (e.g., peptide 20) agonist are key research fields.
Research on obese mice suggests that unimolecular poly-pharmacology is an effective means to deal with various mechanisms leading to obesity and further indicates that GCGR activation is the distinguishing factor between single or double agonists and triple agonists of incretin receptors (127). Studies in knock-out mice confirms the significant potential for novel triple-acting hybrid peptides as therapeutic options for obesity (128). Five clinical trials (SURPASS 1-5 trials) conducted in patients with T2DM showed that tirzepatide at 5-15 mg per week could reduce body weight (5.4-11.7kg), which was never seen with a single drug (129). Karagiannis et al. found that tezepatide had a significant dose-dependent advantage in weight loss compared with placebo, GLP-1R agonists, and basal insulin (130). Zhao et al. provide valuable insights into the structural basis of the functional versatility of tirzepatide and peptide 20 by cryo-electron microscopy (126). Researchers interested in this direction can see more details on the efficacy of GLP-1R/GCGR agonists in the treatment of obesity in Sanchez-Garrido’s review (131).
GLP-1R agonists improve glucose homeostasis in patients with T2DM, cause weight loss, and benefit cardiovascular health over time. However, dose-dependent gastrointestinal effects limit efficacy, so drugs with GLP-1 and GCG pharmacology can also target alternative pathways and may expand the therapeutic index (132).
5 Future research outlook
Over a relatively short period, obesity is a significant public health problem rising. Despite numerous studies, the causes of the obesity epidemic are still not fully understood, and traditional calorie-restricted diets still lack long-term effects (133). It needs effective prevention and treatment. Weight loss surgery may be the most effective treatment for morbid obesity, but we need less radical choices, such as drugs (134). However, obesity is a global health challenge with few drug options (100). The long-term weight-loss agents approved by the FDA of the United States are orlistat, lorcaserin, naltrexone-bupropion, topiramate phenylacetate, LIR, SMG etc. (20). Orlistat is the only weight-reducing drug approved for marketing in China so far. However, these diet pills are controversial because of their safety and long-term efficacy (135, 136). In 2005, a new treatment of T2DM based on the action of GLP-1 was introduced (137). Two GLP-1R agonists have been approved in the United States to treat obesity: semaglutide and LIR, both of which are injected subcutaneously. Whether the patient has diabetes or not, these drugs should be the first-line drugs for obesity (138). For patients with diabetes, the side effects, injection demand, and cost of these drugs should be weighed against the effects of improving blood glucose and losing weight. Currently, GLP-1R agonists are mainly targeted on the endogenous GLP-1R signaling system, which causes GLP-1R agonists to have many pharmacodynamic characteristics like GLP-1. These drugs vary, like changing pharmacokinetics, and different drugs have different dose plans for daily or weekly injections (139).
Besides lowering blood glucose and reducing weight (incredibly visceral fat), GLP-1R agonists can also lower blood pressure, improve blood lipid disorder, and reduce fatty liver (16, 140). The inhibitory effect of GLP-1 on gastric emptying is dose-dependent, and the use of lower doses of GLP-1 in patients with T2DM may also be suitable for blood glucose control (141). Also, GLP-1R agonists can protect the heart and kidneys, reduce the risk of cardiovascular events, and delay the progress of diabetic nephropathy, which is especially important for people with diabetes. The common adverse reactions of GLP-1R agonists include gastrointestinal reactions, mainly loss of appetite, nausea, vomiting, diarrhea, abdominal pain, etc., primarily mild or moderate. To alleviate the gastrointestinal reaction of patients, at the beginning of the application of these drugs, clinical workers should know that the dosage should be gradually increased from a small dosage to enhance patients’ tolerance. Generally, single use will not lead to hypoglycemia, but if combined with sulfonylureas or insulin, attention should be paid to prevent hypoglycemia (142). Other adverse reactions are rare, such as pancreatitis and rash.
Given that GLP-1R agonists have superior weight loss effects and good safety, some of its products have been officially approved by FDA for chronic weight management of obese or overweight adults. The GLP-1R agonists are promising candidates for the treatment of obesity. Currently, except for LIR and SMG, the numbers of related clinical studies of other GLP-1R agonists are few, especially in obese or overweight people without diabetes. Meanwhile, research on the mechanism and efficacy of GLP-1R/GIPR dual agonists and GLP-1R/GIPR/GCGR triple agonists paves the way to a ground-breaking therapy specific for obesity, which suggests multi-target drugs may have more advantages than a single target. Together, GLP-1R, GIPR, and GCGR agonists are expected to see more clinical trial evidence to prove their efficacy and safety in treating obese patients.
Pedrosa et al. (143) summed up GLP-1R agonists to treat obesity and prevent cardiovascular disease. Liu et al. (144) expounded on the modified GLP-1R agonists from the perspective of the patent. Jensterle et al. (145) presented the primary outcomes of clinical trial programs called SCALE and STEP and studies on the efficacy of GLP-1R agonists in pediatric obesity. In this review, we will mainly focus on introducing GLP-1R agonists and trials, and briefly describe the latest research progress of double or triple-target drugs. We anticipate that this study will help biomedical researchers or clinical workers to treat obesity by providing ideas for developing novel drug strategies or scientific research ideas.
Author contributions
J-YW and Q-WW wrote the first draft of the manuscript. D-RL, J-YJ, and H-CZ revised the manuscript. WY and X-YY made the figures and table. X-FZ critically revised the manuscript. All authors contributed to the article and approved the submitted version.
Funding
This study was supported by the National Science Foundation of China (No. 82070362).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Abbreviations
BMI, Body mass index; BN, Beinaglutide; CRP, C-reactive protein; DPP-4, Dipeptidyl peptidase 4; DUL, Dulaglutide; EX, Exenatide EX-LAR, Long-acting release formulation of exenatide; FDA, Food and Drug Administration; FGF, Fibroblast growth factor; IGB, Intragastric balloon; GCG, Glucagon; GLP-1, Glucagon-like peptide-1; GLP-2, Glucagon-like peptide-2; GIP, Gastric inhibitory polypeptide; GI, Gastrointestinal; GLP-1R, Glucagon-like peptide-1 receptor; LIR, Liraglutide; LIXI, Lixisenatide; NEFA, Non-esterified fatty acids; NASH, Nonalcoholic steatohepatitis; OXM, Oxyntomodulin; PEX-168, Polyethylene glycol loxenatide; SMG, Semaglutide; SIRT1, Sirtuin-1; T2DM, Type 2 diabetes.
References
1. Malik VS, Willet WC, Hu FB. Nearly a decade on — trends, risk factors and policy implications in global obesity. Nat Rev Endocrinol (2020) 16:615–6. doi: 10.1038/s41574-020-00411-y
2. Jackson VM, Breen DM, Fortin J-P, Liou A, Kuzmiski JB, Loomis AK, et al. Latest approaches for the treatment of obesity. Expert Opin Drug Discovery (2015) 10:825–39. doi: 10.1517/17460441.2015.1044966
3. Perez-Campos E, Mayoral L-C, Andrade G, Mayoral E-C, Huerta T, Canseco S, et al. Obesity subtypes, related biomarkers & heterogeneity. Indian J Med Res (2020) 151:11. doi: 10.4103/ijmr.IJMR_1768_17
4. Condon C. The fat bomb exploded but no one heard the bang. Eur J Cardiovasc Nurs (2006) 5:99–101. doi: 10.1016/j.ejcnurse.2005.12.003
5. Shukla A, Kumar K, Singh A. Association between obesity and selected morbidities: A study of BRICS countries. PloS One (2014) 9:e94433. doi: 10.1371/journal.pone.0094433
6. Hainer V, Toplak H, Mitrakou A. Treatment modalities of obesity. Diabetes Care (2008) 31:S269–77. doi: 10.2337/dc08-s265
7. Conway B, Rene A. Obesity as a disease: no lightweight matter. Obes Rev (2004) 5:145–51. doi: 10.1111/j.1467-789X.2004.00144.x
8. Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol (2019) 15:288–98. doi: 10.1038/s41574-019-0176-8
9. Ma C, Avenell A, Bolland M, Hudson J, Stewart F, Robertson C, et al. Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis. BMJ (2017) 359:j4849. doi: 10.1136/bmj.j4849
10. Cooper TC, Simmons EB, Webb K, Burns JL, Kushner RF. Trends in weight regain following roux-en-Y gastric bypass (RYGB) bariatric surgery. Obes Surg (2015) 25:1474–81. doi: 10.1007/s11695-014-1560-z
11. Tsesmeli N, Coumaros D. Review of endoscopic devices for weight reduction: old and new balloons and implantable prostheses. Endoscopy (2009) 41:1082–9. doi: 10.1055/s-0029-1215269
12. Folli F, Guardado Mendoza R. Potential use of exenatide for the treatment of obesity. Expert Opin Investig Drugs (2011) 20:1717–22. doi: 10.1517/13543784.2011.630660
13. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art - PubMed. Available at: https://pubmed.ncbi.nlm.nih.gov/33068776/ (Accessed November 14, 2022).
14. Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet (2021) 398:262–76. doi: 10.1016/S0140-6736(21)00536-5
15. Gutniak M, Ørkov C, Holst JJ, Ahrén B, Efendić S. Antidiabetogenic effect of glucagon-like peptide-1 (7–36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med (1992) 326:1316–22. doi: 10.1056/NEJM199205143262003
16. Nauck MA. Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective. Acta Diabetol (1998) 35:117–29. doi: 10.1007/s005920050116
17. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC. Exon duplication and divergence in the human preproglucagon gene. Nature (1983) 304:368–71. doi: 10.1038/304368a0
18. D’Alessio D. IsGLP-1 a hormone: Whether and when? J Diabetes Investig (2016) 7:50–5. doi: 10.1111/jdi.12466
19. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab (2018) 27:740–56. doi: 10.1016/j.cmet.2018.03.001
20. Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, et al. Association of pharmacological treatments for obesity with weight loss and adverse events. JAMA (2016) 315:2424. doi: 10.1001/jama.2016.7602
21. Uptodate . Available at: https://www.uptodate.cn/contents/search.
22. Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V. Attenuated GLP-1 secretion in obesity: cause or consequence? Gut (1996) 38:916–9. doi: 10.1136/gut.38.6.916
23. Ranganath L, Norris F, Morgan L, Wright J, Marks V. Inhibition of carbohydrate-mediated glucagon-like peptide-I (7–36)amide secretion by circulating non-esterified fatty acids. Clin Sci (1999) 96:335–42. doi: 10.1042/cs0960335
24. Vrang N, Larsen PJ. Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: Role of peripherally secreted and centrally produced peptides. Prog Neurobiol (2010) 92:442–62. doi: 10.1016/j.pneurobio.2010.07.003
25. Larsen P, Vrang N, Tang-Christensen M. Central pre-proglucagon derived peptides: Opportunities for treatment of obesity. Curr Pharm Des (2003) 9:1373–82. doi: 10.2174/1381612033454775
26. Baggio LL, Huang Q, Brown TJ, Drucker DJ, Baggio LL, Huang Q, et al. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology (2004) 127:546–58. doi: 10.1053/j.gastro.2004.04.063
27. Smits MM, Tonneijck L, Muskiet MHA, Kramer MHH, Cahen DL, van Raalte DH. Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas. Diabetes Obes Metab (2016) 18:224–35. doi: 10.1111/dom.12593
28. Kanoski SE, Hayes MR, Skibicka KP. GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol-Regul Integr Comp Physiol (2016) 310:R885–95. doi: 10.1152/ajpregu.00520.2015
29. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, LIR and exendin-4 . Available at: https://pubmed.ncbi.nlm.nih.gov/21693680/ (Accessed August 9, 2022).
30. Grill HJ, Hayes MR. Hindbrain neurons as an essential hub in the neuroanatomically distributed control of energy balance. Cell Metab (2012) 16:296–309. doi: 10.1016/j.cmet.2012.06.015
31. Alhadeff AL, Baird J-P, Swick JC, Hayes MR, Grill HJ. Glucagon-like peptide-1 receptor signaling in the lateral parabrachial nucleus contributes to the control of food intake and motivation to feed. Neuropsychopharmacology (2014) 39:2233–43. doi: 10.1038/npp.2014.74
32. Alhadeff AL, Rupprecht LE, Hayes MR. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology (2012) 153:647–58. doi: 10.1210/en.2011-1443
33. Dickson SL, Shirazi RH, Hansson C, Bergquist F, Nissbrandt H, Skibicka KP. The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: A new role for mesolimbic GLP-1 receptors. J Neurosci (2012) 32:4812–20. doi: 10.1523/JNEUROSCI.6326-11.2012
34. Merchenthaler I, Lane M, Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol (1999) 403:261–80. doi: 10.1002/(sici)1096-9861(19990111)403:2<261::aid-cne8>3.0.co;2-5
35. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev (2007) 87:1409–39. doi: 10.1152/physrev.00034.2006
36. Beiroa D, Imbernon M, Gallego R, Senra A, Herranz D, Villarroya F, et al. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Diabetes (2014) 63:3346–58. doi: 10.2337/db14-0302
37. Burmeister MA, Ayala J, Drucker DJ, Ayala JE. Central glucagon-like peptide 1 receptor-induced anorexia requires glucose metabolism-mediated suppression of AMPK and is impaired by central fructose. Am J Physiol-Endocrinol Metab (2013) 304:E677–85. doi: 10.1152/ajpendo.00446.2012
38. Kooijman S, Wang Y, Parlevliet ET, Boon MR, Edelschaap D, Snaterse G, et al. Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice. Diabetologia (2015) 58:2637–46. doi: 10.1007/s00125-015-3727-0
39. Xu F, Lin B, Zheng X, Chen Z, Cao H, Xu H, et al. GLP-1 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1. Diabetologia (2016) 59:1059–69. doi: 10.1007/s00125-016-3896-5
40. Zhang YL, Zhou C, Li XF, Yang MN, Tao L, Zheng XY, et al. Beinaglutide showed significant weight-loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real-world setting: a 3-month, multicentre, observational, retrospective, open-label study. Obes Sci Amp Pract (2019) 5:366–75. doi: 10.1002/osp4.342
41. Wang G, Wu P, Qiu Y, Dong X, Wang Y, Chi Y, et al. Effect of beinaglutide treatment on weight loss in Chinese patients with type 2 diabetes mellitus and overweight/obesity. Arch Endocrinol Metab (2021) 65:421–7. doi: 10.20945/2359-3997000000388
42. Fang X, Du Z, Duan C, Zhan S, Wang T, Zhu M, et al. Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse model. Life Sci (2021) 270:118966. doi: 10.1016/j.lfs.2020.118966
43. Gao L, Huang H, Zhang L, Zhang N, Fu Y, Zhu D, et al. Comparison of beinaglutide versus metformin for weight loss in overweight and obese non-diabetic patients. Exp Clin Endocrinol Amp Diabetes (2022) 130:358–67. doi: 10.1055/a-1608-0345
44. Ding B, Hu Y, Yuan L, Yan R-N, Ma J-H. Effectiveness of beinaglutide in a patient with late dumping syndrome after gastrectomy. Med (Baltimore) (2021) 100:e26086. doi: 10.1097/MD.0000000000026086
45. Zhang F, Chen Z, Wu D, Tian L, Chen Q, Ye Y, et al. Recombinant human GLP-1 beinaglutide regulates lipid metabolism of adipose tissues in diet-induced obese mice. iScience (2021) 24:103382. doi: 10.1016/j.isci.2021.103382
46. Barnett A. Exenatide. Expert Opin Pharmacother (2007) 8:2593–608. doi: 10.1517/14656566.8.15.2593
48. Simonsen L, Holst JJ, Deacon CF. Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs. Diabetologia (2006) 49:706–12. doi: 10.1007/s00125-005-0128-9
49. Nishi H, Higashihara T, Inagi R. Lipotoxicity in kidney, heart, and skeletal muscle dysfunction. Nutrients (2019) 11:1664. doi: 10.3390/nu11071664
50. Wang Y, He W, Wei W, Mei X, Yang M, Wang Y. Exenatide attenuates obesity-induced mitochondrial dysfunction by activating SIRT1 in renal tubular cells. Front Endocrinol (2021) 12:622737. doi: 10.3389/fendo.2021.622737
51. Moretto T, Milton D, Ridge T, Macconell L, Okerson T, Wolka A, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug–naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther (2008) 30:1448–60. doi: 10.1016/j.clinthera.2008.08.006
52. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD, et al. Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care (2004) 27:2628–35. doi: 10.2337/diacare.27.11.2628
53. Apovian CM, Bergenstal RM, Cuddihy RM, Qu Y, Lenox S, Lewis MS, et al. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med (2010) 123:468. doi: 10.1016/j.amjmed.2009.11.019
54. Rosenstock J, Klaff LJ, Schwartz S, Northrup J, Holcombe JH, Wilhelm K, et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care (2010) 33:1173–5. doi: 10.2337/dc09-1203
55. Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab (2008) 93:2670–8. doi: 10.1210/jc.2008-0115
56. González-Ortiz M, Martínez-Abundis E, Robles-Cervantes JA, Ramos-Zavala MG. Effect of exenatide on fat deposition and a metabolic profile in patients with metabolic syndrome. Metab Syndr Relat Disord (2011) 9:31–4. doi: 10.1089/met.2010.0025
57. Iepsen EW, Torekov SS, Holst JJ. Therapies for inter-relating diabetes and obesity – GLP-1 and obesity. Expert Opin Pharmacother (2014) 15:2487–500. doi: 10.1517/14656566.2014.965678
58. Anderson SL, Trujillo JM. Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness. Ther Adv Chronic Dis (2016) 7:4–17. doi: 10.1177/2040622315609312
59. Christensen M, Knop FK, Holst JJ, Vilsboll T. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs Investig Drugs J (2009) 12:503–13.
60. Petersen AB, Knop FK, Christensen M. Lixisenatide for the treatment of type 2 diabetes. Drugs Today (Barc) (2013) 49(9):537–53. doi: 10.1358/dot.2013.49.9.2020940
61. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med (2015) 373:2247–57. doi: 10.1056/NEJMoa1509225
62. Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE, et al. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy. Diabetes Care (2012) 35:1225–31. doi: 10.2337/dc11-1935
63. McCarty D, Coleman M, Boland CL. Lixisenatide: A new daily GLP-1 agonist for type 2 diabetes management. Ann Pharmacother (2017) 51:401–9. doi: 10.1177/1060028017689878
64. Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus. Available at: https://pubmed.ncbi.nlm.nih.gov/24087882/ (Accessed August 10, 2022).
65. Forst T, Pfützner A. Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus. Expert Opin Pharmacother (2013) 14:2281–96. doi: 10.1517/14656566.2013.838559
66. Christensen M, Miossec P, Larsen BD, Werner U, Knop FK. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus. Expert Opin Drug Discovery (2014) 9:1223–51. doi: 10.1517/17460441.2014.942638
67. Horowitz M, Rayner CK, Jones KL. Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes. Adv Ther (2013) 30:81–101. doi: 10.1007/s12325-013-0009-4
68. Roca-Rodríguez MM, Muros de Fuentes MT, Piédrola-Maroto G, Quesada-Charneco M, Maraver-Selfa S, Tinahones FJ, et al. Lixisenatida en pacientes con diabetes tipo 2 y obesidad: más allá del control glucémico. Aten Primaria (2017) 49:294–9. doi: 10.1016/j.aprim.2016.06.009
69. Whyte MB, Shojaee-Moradie F, Sharaf SE, Jackson NC, Fielding B, Hovorka R, et al. Lixisenatide reduces chylomicron triacylglycerol by increased clearance. J Clin Endocrinol Metab (2019) 104:359–68. doi: 10.1210/jc.2018-01176
70. Kaneto H, Takami A, Spranger R, Amano A, Watanabe D, Niemoeller E. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-l randomized clinical trial. Diabetes Obes Metab (2020) 22:3–13. doi: 10.1111/dom.14005
71. Riddle MC, Aronson R, Home P, Marre M, Niemoeller E, Miossec P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin. Diabetes Care (2013) 36:2489–96. doi: 10.2337/dc12-2454
72. Rosenstock J, Hanefeld M, Shamanna P, Min KW, Boka G, Miossec P, et al. Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-s). J Diabetes Complications (2014) 28:386–92. doi: 10.1016/j.jdiacomp.2014.01.012
73. Bolli GB, Munteanu M, Dotsenko S, Niemoeller E, Boka G, Wu Y, et al. Efficacy and safety of lixisenatide once daily vs. placebo in people with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). Diabetes Med (2014) 31:176–84. doi: 10.1111/dme.12328
74. Onishi Y, Niemoeller E, Ikeda Y, Takagi H, Yabe D, Seino Y. Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of G et G oal- s. J Diabetes Investig (2015) 6:201–9. doi: 10.1111/jdi.12275
75. Nauck M, Rizzo M, Johnson A, Bosch-Traberg H, Madsen J, Cariou B. Once-daily liraglutide versus lixisenatide as add-on to metformin in type 2 diabetes: A 26-week randomized controlled clinical trial. Diabetes Care (2016) 39:1501–9. doi: 10.2337/dc15-2479
76. Ahrén B, Leguizamo Dimas A, Miossec P, Saubadu S, Aronson R. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-m). Diabetes Care (2013) 36:2543–50. doi: 10.2337/dc12-2006
77. Rosenstock J, Raccah D, Korányi L, Maffei L, Boka G, Miossec P, et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin. Diabetes Care (2013) 36:2945–51. doi: 10.2337/dc12-2709
78. Hunt B, Kragh N, McConnachie CC, Valentine WJ, Rossi MC, Montagnoli R. Long-term cost-effectiveness of two GLP-1 receptor agonists for the treatment of type 2 diabetes mellitus in the Italian setting: Liraglutide versus lixisenatide. Clin Ther (2017) 39:1347–59. doi: 10.1016/j.clinthera.2017.05.354
79. Leon N, LaCoursiere R, Yarosh D, Patel RS. Lixisenatide (Adlyxin). Pharm Ther (2017) 42:676–711.
80. Russell-Jones D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Mol Cell Endocrinol (2009) 297:137–40. doi: 10.1016/j.mce.2008.11.018
81. Knudsen LB, Agersoe H, Huusfeldt PO, Nielsen PF, Wilken M. Derivatives of glucagon-like peptide-1 suitable for once daily administration. Diabetes (1999) 48:SA202–2.
82. Madsen K, Knudsen LB, Agersoe H, Nielsen PF, Thøgersen H, Wilken M, et al. Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. J Med Chem (2007) 50:6126–32. doi: 10.1021/jm070861j
83. Wilding JPH, Overgaard RV, Jacobsen LV, Jensen CB, le Roux CW. Exposure-response analyses of liraglutide 3.0 mg for weight management. Diabetes Obes Metab (2016) 18:491–9. doi: 10.1111/dom.12639
84. Manigault KR, Thurston MM. Liraglutide: A glucagon-like peptide-1 agonist for chronic weight management. Consult Pharm (2016) 31:685–97. doi: 10.4140/TCP.n.2016.685
85. Liraglutide: A new option for the treatment of obesity . Available at: https://pubmed.ncbi.nlm.nih.gov/26497479/ (Accessed August 10, 2022).
86. Zhu E, Yang Y, Zhang J, Li Y, Li C, Chen L, et al. Liraglutide suppresses obesity and induces brown fat-like phenotype via soluble guanylyl cyclase mediated pathwayin vivoandin vitro. Oncotarget (2016) 7:81077–89. doi: 10.18632/oncotarget.13189
87. Pinelli NR, Hurren KM. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: A systematic review and meta-analysis. Ann Pharmacother (2011) 45:850–60. doi: 10.1345/aph.1Q024
88. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean MEJ, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (2012) 36:843–54. doi: 10.1038/ijo.2011.158
89. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet (2009) 374:1606–16. doi: 10.1016/S0140-6736(09)61375-1
90. Lean MEJ, Carraro R, Finer N, Hartvig H, Lindegaard ML, Rössner S, et al. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes (2014) 38:689–97. doi: 10.1038/ijo.2013.149
91. le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet (2017) 389:1399–409. doi: 10.1016/S0140-6736(17)30069-7
92. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med (2015) 373:11–22. doi: 10.1056/NEJMoa1411892
93. Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE maintenance randomized study. Int J Obes (2013) 37:1443–51. doi: 10.1038/ijo.2013.120
94. Bode B. Liraglutide: A review of the first once-daily GLP-1 receptor agonist. Am J Manag Care (2011) 17(2 Suppl):s59–70.
95. Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (2019) 10:155. doi: 10.3389/fendo.2019.00155
96. Christou GA, Katsiki N, Blundell J, Fruhbeck G, Kiortsis DN. Semaglutide as a promising antiobesity drug. Obes Rev (2019) 20:805–15. doi: 10.1111/obr.12839
97. STEP 1 for effective weight control - another first step? Available at: https://pubmed.ncbi.nlm.nih.gov/33567184/ (Accessed August 10, 2022).
98. Rosenstock J, Allison D, Birkenfeld AL, Blicher TM, Deenadayalan S, Jacobsen JB, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea. JAMA (2019) 321:1466. doi: 10.1001/jama.2019.2942
99. Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet (2021) 397:971–84. doi: 10.1016/S0140-6736(21)00213-0
100. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med (2021) 384:989–1002. doi: 10.1056/NEJMoa2032183
101. Rubino DM, Greenway FL, Khalid U, O’Neil PM, Rosenstock J, Sørrig R, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes. JAMA (2022) 327:138. doi: 10.1001/jama.2021.23619
102. Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity. JAMA (2021) 325:1403. doi: 10.1001/jama.2021.1831
103. Cowart K. Oral semaglutide: first-in-class oral GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Ann Pharmacother (2020) 54(5):478–85. doi: 10.1177/1060028019889064
104. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial . Available at: https://pubmed.ncbi.nlm.nih.gov/?term=+Effect+of+Weekly+Subcutaneous+Semaglutide+vs+Daily+Liraglutide+on+Body+Weight+in+Adults+With+Overweight+or+Obesity+Without+Diabetes%3A+The+STEP+8+Randomized+Clinical+Trial&size=100 (Accessed August 10, 2022).
105. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial . Available at: https://pubmed.ncbi.nlm.nih.gov/31189511/ (Accessed August 10, 2022).
106. Østergaard L, Frandsen CS, Madsbad S. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review. Expert Rev Clin Pharmacol (2016) 9:241–65. doi: 10.1586/17512433.2016.1121808
107. Jendle J, Grunberger G, Blevins T, Giorgino F, Hietpas RT, Botros FT. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes Metab Res Rev (2016) 32:776–90. doi: 10.1002/dmrr.2810
108. Barrington P, Chien JY, Showalter HDH, Schneck K, Cui S, Tibaldi F, et al. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. Diabetes Obes Metab (2011) 13:426–33. doi: 10.1111/j.1463-1326.2011.01364.x
109. Dungan KM, Povedano ST, Forst T, González JGG, Atisso C, Sealls W, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet (2014) 384:1349–57. doi: 10.1016/S0140-6736(14)60976-4
110. Umpierrez G, Tofé Povedano S, Pérez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care (2014) 37:2168–76. doi: 10.2337/dc13-2759
111. Frias JP, Bonora E, Nevarez Ruiz L, Li YG, Yu Z, Milicevic Z, et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care (2021) 44:765–73. doi: 10.2337/dc20-1473
112. Giorgino F, Benroubi M, Sun J-H, Zimmermann AG, Pechtner V. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care (2015) 38:2241–9. doi: 10.2337/dc14-1625
113. Zhou Y, Zhu J, Wu H, Deng Y, Ji Q. Pancreatic safety of once-weekly dulaglutide in Chinese patients with type 2 diabetes mellitus: Subgroup analysis by potential influencing factors. Diabetes Ther (2021) 12:2677–90. doi: 10.1007/s13300-021-01139-2
114. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol (2012) 8:728–42. doi: 10.1038/nrendo.2012.140
115. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet (2008) 372:1240–50. doi: 10.1016/S0140-6736(08)61206-4
116. Norwood P, Liutkus JF, Haber H, Pintilei E, Boardman MK, Trautmann ME. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years. Clin Ther (2012) 34:2082–90. doi: 10.1016/j.clinthera.2012.09.007
117. Elkind-Hirsch KE, Chappell N, Seidemann E, Storment J, Bellanger D. Exenatide, dapagliflozin, or Phentermine/Topiramate differentially affect metabolic profiles in polycystic ovary syndrome. J Clin Endocrinol Metab (2021) 106:3019–33. doi: 10.1210/clinem/dgab408
118. Malone J, Trautmann M, Wilhelm K, Taylor K, Kendall DM. Exenatide once weekly for the treatment of type 2 diabetes. Expert Opin Investig Drugs (2009) 18:359–67. doi: 10.1517/13543780902766802
119. Zhang Y, Li Y, Zhao J, Wang C, Deng B, Zhang Q, et al. Protective effects and mechanisms of polyethylene glycol loxenatide against hyperglycemia and liver injury in db/db diabetic mice. Front Pharmacol (2021) 12:781856. doi: 10.3389/fphar.2021.781856
120. Guo Z, Wu Y, Zhu L, Wang Y, Wang D, Sun X. PEX-168 improves insulin resistance, inflammatory response and adipokines in simple obese mice: a mechanistic exploration. BMC Endocr Disord (2021) 21:245. doi: 10.1186/s12902-021-00908-1
121. Shuai Y, Yang G, Zhang Q, Li W, Luo Y, Ma J, et al. Efficacy and safety of polyethylene glycol loxenatide monotherapy in type 2 diabetes patients: A multicentre, randomized, double-blind, placebo-controlled phase 3a clinical trial. Diabetes Obes Metab (2021) 23:116–24. doi: 10.1111/dom.14198
122. Yang G-R, Zhao X-L, Jin F, Shi L-H, Yang J-K. Pharmacokinetics and pharmacodynamics of a polyethylene glycol (PEG)-conjugated GLP-receptor agonist once weekly in Chinese patients with type 2 diabetes. J Clin Pharmacol (2015) 55:152–8. doi: 10.1002/jcph.386
123. Wang J, Huang J, Li W, Tang S, Sun J, Zhang X, et al. Polyethylene glycol loxenatide (PEX168) in subjects with renal impairment: A pharmacokinetic study. Br J Clin Pharmacol (2019) 85:2714–20. doi: 10.1111/bcp.14091
124. Seino Y, Fukushima M, Yabe D, Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: Similarities and differences. J Diabetes Investig (2010) 1:8–23. doi: 10.1111/j.2040-1124.2010.00022.x
125. Kleinert M, Sachs S, Habegger KM, Hofmann SM, Müller TD, Kleinert M, et al. Glucagon regulation of energy expenditure. Int J Mol Sci (2019) 20:5407. doi: 10.3390/ijms20215407
126. Zhao F, Zhou Q, Cong Z, Hang K, Zou X, Zhang C, et al. Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors. Nat Commun (2022) 13:1057. doi: 10.1038/s41467-022-28683-0
127. Knerr PJ, Mowery SA, Douros JD, Premdjee B, Hjøllund KR, He Y, et al. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice. Mol Metab (2022) 63:101533. doi: 10.1016/j.molmet.2022.101533
128. Gault VA, Bhat VK, Irwin N, Flatt PR, Gault VA, Bhat VK, et al. A novel glucagon-like peptide-1 (GLP-1)/Glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice. J Biol Chem (2013) 288:35581–91. doi: 10.1074/jbc.M113.512046
129. Nauck MA, D’Alessio DA, Nauck MA, D’Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol (2022) 21:169. doi: 10.1186/s12933-022-01604-7
130. Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia (2022) 65:1251–61. doi: 10.1007/s00125-022-05715-4
131. Sánchez-Garrido MA, Brandt SJ, Clemmensen C, Müller TD, DiMarchi RD, Tschöp MH, et al. GLP-1/glucagon receptor co-agonism for treatment of obesity. Diabetologia (2017) 60:1851–61. doi: 10.1007/s00125-017-4354-8
132. Samms RJ, Coghlan MP, Sloop KW, Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Amp Metab (2020) 31:410–21. doi: 10.1016/j.tem.2020.02.006
133. Ludwig DS, Ebbeling CB. The carbohydrate-insulin model of obesity. JAMA Intern Med (2018) 178:1098. doi: 10.1001/jamainternmed.2018.2933
134. Perez-Montes DE Oca A, Pellitero S, Puig-Domingo M. Obesity and GLP-1. Minerva Endocrinol (2021) 46:168–76. doi: 10.23736/S2724-6507.20.03369-6
135. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions. Drug Saf (2008) 31:53–65. doi: 10.2165/00002018-200831010-00005
136. Greig SL, Keating GM. Naltrexone ER/Bupropion ER: A review in obesity management. Drugs (2015) 75:1269–80. doi: 10.1007/s40265-015-0427-5
137. Gallwitz B. Glucagon-like peptide–1 analogues for type 2 diabetes mellitus. Drugs (2011) 71:1675–88. doi: 10.2165/11592810-000000000-00000
139. Hirsch IB. The future of the GLP-1 receptor agonists. JAMA (2019) 321:1457. doi: 10.1001/jama.2019.2941
140. Nauck MA. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. Horm Metab Res (2004) 36:852–8. doi: 10.1055/s-2004-826175
141. Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab (2003) 88:2719–25. doi: 10.1210/jc.2003-030049
142. Stonehouse AH, Holcombe JH, Kendall DM. Management of type 2 diabetes: the role of incretin mimetics. Expert Opin Pharmacother (2006) 7:2095–105. doi: 10.1517/14656566.7.15.2095
143. Pedrosa MR, Franco DR, Gieremek HW, Vidal CM, Bronzeri F, de Cassia Rocha A, et al. GLP-1 agonist to treat obesity and prevent cardiovascular disease: What have we achieved so far? Curr Atheroscler Rep (2022) 24:867–84. doi: 10.1007/s11883-022-01062-2
144. Liu C, Zou Y, Qian H, Liu C, Zou Y, Qian H. GLP-1R agonists for the treatment of obesity: a patent review (2015-present). Expert Opin Ther Pat (2020) 30:781–94. doi: 10.1080/13543776.2020.1811851
Keywords: GLP-1R agonists, obesity, weight-reducing drugs, metabolic diseases, dual agonism
Citation: Wang J-Y, Wang Q-W, Yang X-Y, Yang W, Li D-R, Jin J-Y, Zhang H-C and Zhang X-F (2023) GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach. Front. Endocrinol. 14:1085799. doi: 10.3389/fendo.2023.1085799
Received: 31 October 2022; Accepted: 02 January 2023;
Published: 01 February 2023.
Edited by:
Xiaodong Sun, Affiliated Hospital of Weifang Medical University, ChinaReviewed by:
Kefei Dou, Chinese Academy of Medical Sciences and Peking Union Medical College, ChinaFinbarr P. M. O’Harte, Ulster University, United Kingdom
Copyright © 2023 Wang, Wang, Yang, Yang, Li, Jin, Zhang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xian-Feng Zhang, emhhbmd4aWFuZkBqbHUuZWR1LmNu
†These authors have contributed equally to this work and share first authorship